Merck said on Wednesday that its experimental oral HIV treatment was not inferior to Gilead's top-selling HIV drug Biktarvy ...
A Brazilian research team has eliminated HIV from a patient’s body for 78 consecutive weeks using only medications, without ...
Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...
African kingdom has accepted 15 men as part of a third-country deportation program. This program, which has been strongly ...
Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date.
Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...
Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said the treatment is a once-daily two-drug regimen of doravirine/islatravir that ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...
Primary effectiveness was measured by the number of patients with HIV-1 RNA ≥50 copies/mL at Week 48, as well as the number of patients with a change in CD4 cell count, and the proportion of patients ...
Funding for HIV care and prevention are key for continued progress, but recent cuts to federal funding for health agencies, ...
Indian River County recorded the highest rate of new cases on the Treasure Coast, with 14 per 100,000 people diagnosed with ...
Prof Nawangwe said Makerere University — ranked second in Africa and 63rd globally — continues to bolster its profile as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback